Join Abzena’s Principal Scientist for Bioconjugation, Dr Saptarshi Ghosh and Senior Bioconjugation Scienist, Austin McKinsey, on Dec. 13th for a live webinar that will focus on how to take a next-generation conjugate through lead candidate selection and technical development.
This webinar will focus on critical design and process development steps to ensure the optimization and scale-up of ADCs and bioconjugates. By starting smart, we can finish fast and maximize chances of success. It will cover the following areas:
DESIGNING NEXT-GENERATION BIOCONJUGATES
- Selecting Target and Targeting Moiety
- From Linker-Payload to Conjugate
PROCESS DEVELOPMENT AND MANUFACTURING CONSIDERATIONS FOR NEXT-GENERATION CONJUGATES
- Incorporating Next-Generation Conjugation Technologies into ADC Manufacturing – Engineered Cysteines ADCs
- Manufacturing Strategies for Novel Payloads Conjugates – Radioimmunoconjugates and Oligonucleotides Conjugates
- Considerations for designing next-generation bioconjugates.
- Process development and manufacturing considerations for next-generation conjugates.
About Our Speakers
Principal scientist at Abzena focusing on Early to Late Phase bioconjugation development and manufacturing of ADCs.
–R&D lead for novel-format bioconjugation strategies and development.
–Led projects for integrated programs supporting batch execution, tech transfer and providing manufacturing support for ADCs.
Background in chemical biology, bioconjugation and biorthogonal chemistry
–Doctoral work in the field of biorthogonal chemistry, working with novel intramolecular lewis acid catalyzed click reactions.
-Developed novel strategies to combine enzymatic and click reactions in single vessel immunoprecipitation of proteins.
-Ph. D. in Chemistry from State University of New York at Binghamton.
BIOCONJUGATION EXPERT WITH 3 YEARS OF EXPERIENCE IN ADC PROCESS DEVELOPMENT AND MANUFACTURING
Manager at Abzena focusing on Process Development and Manufacture of Bioconjugate Therapies.
–Supporting manufacturing and process development for ADCs and novel-format bioconjugate modalities.
–Development and Manufacture lead for over 8 ADC, Protein-Oligonucleotide conjugates, and Radio-immunoconjugates currently in clinical trials.
Background in viral vector mediated gene-therapy process development and manufacturing.
–Platform development for upstream and downstream processes for AAV and Lenti viral vectors at Wuxi Advanced Therapies.
Bachelors in Pharmacology and Toxicology from University of the Sciences